Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marschner

Showing results (11-20 of 902) with videos related to

Pageof 91
Sort By:
Statistics in Medicine|November 30, 1994
Determining the size of a cross-sectional sample to estimate the age-specific incidence of an irreversible diseaseI C Marschner
Pharmaceutical Statistics|February 27, 2007
Optimal design of clinical trials comparing several treatments with a controlIan C Marschner
Biometrics|June 1, 1996
Fitting a multiplicative incidence model to age- and time-specific prevalence dataI C Marschner
Mathematical Biosciences|April 1, 1992
The effect of preferential mixing on the growth of an epidemicI C Marschner
Clinical Trials (London, England)|March 27, 2010
Regional differences in multinational clinical trials: anticipating chance variationIan C Marschner
Biometrics|January 10, 1998
A method for assessing age-time disease incidence using serial prevalence dataI C Marschner
Epidemiology and Infection|May 19, 2020
Back-projection of COVID-19 diagnosis counts to assess infection incidence and control measures: analysis of Australian dataI C Marschner
BMC Medical Research Methodology|June 22, 2021
Estimating age-specific COVID-19 fatality risk and time to death by comparing population diagnosis and death patterns: Australian dataIan C Marschner
Journal of Environmental Quality|April 20, 2010
Waste effects on the behavior of 17beta-estradiol, estrone, and 17alpha-ethinylestradiol in agricultural soils in long- and short-term setupsBritta Stumpe, Bernd Marschner
Onkologie|August 8, 2012
Long-term disease stabilization in a patient with castration-resistant metastatic prostate cancer by the addition of lenalidomide to low-dose dexamethasone and celecoxibNorbert Marschner, Matthias Zaiss
Pageof 91

Showing results (11-20 of 902) with videos related to

Sort By:
Pageof 91
Statistics in Medicine|November 30, 1994
Determining the size of a cross-sectional sample to estimate the age-specific incidence of an irreversible diseaseI C Marschner
Pharmaceutical Statistics|February 27, 2007
Optimal design of clinical trials comparing several treatments with a controlIan C Marschner
Biometrics|June 1, 1996
Fitting a multiplicative incidence model to age- and time-specific prevalence dataI C Marschner
Mathematical Biosciences|April 1, 1992
The effect of preferential mixing on the growth of an epidemicI C Marschner
Clinical Trials (London, England)|March 27, 2010
Regional differences in multinational clinical trials: anticipating chance variationIan C Marschner
Biometrics|January 10, 1998
A method for assessing age-time disease incidence using serial prevalence dataI C Marschner
Epidemiology and Infection|May 19, 2020
Back-projection of COVID-19 diagnosis counts to assess infection incidence and control measures: analysis of Australian dataI C Marschner
BMC Medical Research Methodology|June 22, 2021
Estimating age-specific COVID-19 fatality risk and time to death by comparing population diagnosis and death patterns: Australian dataIan C Marschner
Journal of Environmental Quality|April 20, 2010
Waste effects on the behavior of 17beta-estradiol, estrone, and 17alpha-ethinylestradiol in agricultural soils in long- and short-term setupsBritta Stumpe, Bernd Marschner
Onkologie|August 8, 2012
Long-term disease stabilization in a patient with castration-resistant metastatic prostate cancer by the addition of lenalidomide to low-dose dexamethasone and celecoxibNorbert Marschner, Matthias Zaiss
Pageof 91